|
|
||||||||
Introduction: Prostate cancer constitutes a major health issue in Western countries where it is now the most frequently diagnosed invasive tumour and second leading cause of cancer deaths (Wingo et al. 1995). Androgen action in prostate cancers, as in the normal prostate gland and other target organs, is mediated by the androgen receptor (AR), a ligand-activated nuclear transcription factor that is a member of the steroid/thyroid hormone receptor gene superfamily (O'Malley 1990, Truss & Beato 1993). Although the human AR has only recently been cloned (Chang et al. 1988, Lubahn et al. 1988, Trapman et al. 1988, Tilley et al. 1989), specific actions of androgens on the growth, differentiation and function of the prostate gland were elucidated early this century. In 1941, Huggins and Hodges demonstrated that, similar to non-malignant prostate, prostate cancers were androgen-responsive and that tumour regression was evident following removal of testicular androgens by castration. More than
This article has been cited by other articles:
![]() |
L. C. Shank, J. B. Kelley, D. Gioeli, C.-S. Yang, A. Spencer, L. A. Allison, and B. M. Paschal Activation of the DNA-dependent Protein Kinase Stimulates Nuclear Export of the Androgen Receptor in Vitro J. Biol. Chem., April 18, 2008; 283(16): 10568 - 10580. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gao, H. Wang, P. Lee, J. Melamed, C. X Li, F. Zhang, H. Wu, L. Zhou, and Z. Wang Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J. Mol. Endocrinol., June 1, 2006; 36(3): 463 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Zeegers, L. A.L.M. Kiemeney, A. M. Nieder, and H. Ostrer How Strong Is the Association Between CAG and GGN Repeat Length Polymorphisms in the Androgen Receptor Gene and Prostate Cancer Risk? Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1765 - 1771. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Buchanan, M. Yang, A. Cheong, J. M. Harris, R. A. Irvine, P. F. Lambert, N. L. Moore, M. Raynor, P. J. Neufing, G. A. Coetzee, et al. Structural and functional consequences of glutamine tract variation in the androgen receptor Hum. Mol. Genet., August 15, 2004; 13(16): 1677 - 1692. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Powzaniuk, S. McElwee-Witmer, R. L. Vogel, T. Hayami, S. J. Rutledge, F. Chen, S.-i. Harada, A. Schmidt, G. A. Rodan, L. P. Freedman, et al. The LATS2/KPM Tumor Suppressor Is a Negative Regulator of the Androgen Receptor Mol. Endocrinol., August 1, 2004; 18(8): 2011 - 2023. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hosohata, P. Li, Y. Hosohata, J. Qin, R. G. Roeder, and Z. Wang Purification and Identification of a Novel Complex Which Is Involved in Androgen Receptor-Dependent Transcription Mol. Cell. Biol., October 1, 2003; 23(19): 7019 - 7029. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Liao, L.-Y. Chen, A. Zhang, A. Godavarthy, F. Xia, J. C. Ghosh, H. Li, and J. D. Chen Regulation of Androgen Receptor Activity by the Nuclear Receptor Corepressor SMRT J. Biol. Chem., February 7, 2003; 278(7): 5052 - 5061. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Gelmann Molecular Biology of the Androgen Receptor J. Clin. Oncol., July 1, 2002; 20(13): 3001 - 3015. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Heinlein and C. Chang Androgen Receptor (AR) Coregulators: An Overview Endocr. Rev., April 1, 2002; 23(2): 175 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Taplin and S.-M. Ho The Endocrinology of Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477. [Full Text] [PDF] |
||||
![]() |
G. Buchanan, N. M. Greenberg, H. I. Scher, J. M. Harris, V. R. Marshall, and W. D. Tilley Collocation of Androgen Receptor Gene Mutations in Prostate Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1273 - 1281. [Abstract] [Full Text] |
||||
![]() |
G. Buchanan, M. Yang, J. M. Harris, H. S. Nahm, G. Han, N. Moore, J. M. Bentel, R. J. Matusik, D. J. Horsfall, V. R. Marshall, et al. Mutations at the Boundary of the Hinge and Ligand Binding Domain of the Androgen Receptor Confer Increased Transactivation Function Mol. Endocrinol., January 1, 2001; 15(1): 46 - 56. [Abstract] [Full Text] |
||||
![]() |
S. M. Henshall, D. I. Quinn, C. S. Lee, D. R. Head, D. Golovsky, P. C. Brenner, W. Delprado, P. D. Stricker, J. J. Grygiel, and R. L. Sutherland Altered Expression of Androgen Receptor in the Malignant Epithelium and Adjacent Stroma Is Associated with Early Relapse in Prostate Cancer Cancer Res., January 1, 2001; 61(2): 423 - 427. [Abstract] [Full Text] |
||||
![]() |
C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text] |
||||
![]() |
D. B. Agus, C. Cordon-Cardo, W. Fox, M. Drobnjak, A. Koff, D. W. Golde, and H. I. Scher Prostate Cancer Cell Cycle Regulators: Response to Androgen Withdrawal and Development of Androgen Independence J Natl Cancer Inst, November 3, 1999; 91(21): 1869 - 1876. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lopez-Otin and E. P. Diamandis Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features Endocr. Rev., August 1, 1998; 19(4): 365 - 396. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Russell, S. Bennett, and P. Stricker Growth factor involvement in progression of prostate cancer Clin. Chem., April 1, 1998; 44(4): 705 - 723. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. J. McEwan and J.-A. Gustafsson Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF PNAS, August 5, 1997; 94(16): 8485 - 8490. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |